biotechnology, was appointed president of Aldevron’s GMP nucleic acids business unit. She will oversee the Fargo company’s strategy to provide GMP plasmids and mRNA for gene editing, gene therapy and cell therapy applications. She previously was vice president of patient affairs and community engagement for Abeona Therapeutics.